Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2

Carcinogenesis

Volumn 34, Issue 5, 2013, Pages 1115-1124

  Witt, Daria ^a   Burfeind, Peter ^a   von Hardenberg, Sandra ^a   Opitz, Lennart ^a   Salinas Riester, Gabriela ^a   Bremmer, Felix ^a   Schweyer, Stefan ^a,c   Thelen, Paul ^a   Neesen, Jürgen ^b   Kaulfuß, Silke ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Gemeinschaftspraxis Pathologie Starnberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D2; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CCND2 GENE; CELL MIGRATION; CELL PROLIFERATION; GENE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR INVASION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN D2; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; VALPROIC ACID;

EID: 84877116728     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt019     Document Type: Article

References (47)

1. American Society of Cancer. (2010) Cancer facts and figures. Atlanta, GA: American Cancer Society.
2. Jemal,A. et al. (2010) Cancer statistics, 2010. CA. Cancer J. Clin., 60, 277-300.
3. Ellis,L. et al. (2009) Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther., 8, 1409-1420.
4. Wang,G.G. et al. (2007) Chromatin remodeling and cancer, Part I: covalent histone modifications. Trends Mol. Med., 13, 363-372.
5. Marks,P. et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer, 1, 194-202.
6. Göttlicher,M. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 20, 6969-6978.
7. Raffoux,E. et al. (2010) Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget, 1, 34-42.
8. Arce,C. et al. (2006) A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE, 1, e98.
9. Chavez-Blanco,A. et al. (2005) Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol. Cancer, 4, 22.
10. Nelson,W.G. et al. (2003) Prostate cancer. N. Engl. J. Med., 349, 366-381.
11. Annicotte,J.S. et al. (2006) Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol. Cell. Biol., 26, 7561-7574.
12. Iacopino,F. et al. (2008) Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. Int. J. Oncol., 32, 1293-1303.
13. Shabbeer,S. et al. (2007) Multiple Molecular pathways explain the antiproliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate, 67, 1099-1110.
14. Stettner,M. et al. (2007) The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol. Cancer Ther., 6, 2626-2633.
15. Wedel,S. et al. (2011) Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin. Exp. Metastasis, 28, 479-491.
16. Xia,Q. et al. (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res., 66, 7237-7244.
17. Chateauvieux,S. et al. (2010) Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol., 2010, 1-19.
18. Sherr,C.J. (1996) Cancer cell cycles. Science, 274, 1672-1677.
19. Delmer,A. et al. (1995) Overexpression of cyclin D2 in chronic B-cell malignancies. Blood, 85, 2870-2876.
20. Takano,Y. et al. (2000) Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am. J. Pathol., 156, 585-594.
21. Igawa,T. et al. (2011) Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma. Cancer Sci., 102, 2103-2107.
22. Henrique,R. et al. (2006) Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J. Mol. Med., 84, 911-918.
23. Padar,A. et al. (2003) Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res., 9, 4730-4734.
24. Kobayashi,T. et al. (2009) Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells. Biochem. Biophys. Res. Commun., 387, 196-201.
25. Ko,E. et al. (2012) Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer. Lung Cancer, 77, 401-406.
26. Musgrove,E.A. et al. (2011) Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer, 11, 558-572.
27. Kaulfuß,S. et al. (2009) Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression. Oncogene, 28, 3971-3982.
28. Uhmann,A. et al. (2011) Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling and differentiation. Mol. Cancer Ther., 10, 2179-2188.
29. Kaulfuss,S. et al. (2008) Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells. Mol. Endocrinol., 22, 1606-1621.
30. Venkataramani,V. et al. (2010) Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J. Biol. Chem., 285, 10678-10689.
31. Meyer,S. et al. (2010) Pluripotent embryonic stem cells and multipotent adult germline stem cells reveal similar transcriptomes including pluripotency-related genes. Mol. Hum. Reprod., 16, 846-855.
32. Greenberg,N.M. et al. (1995) Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U.S.A., 92, 3439-3443.
33. Toubaji,A. et al. (2012) Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases. Hum. Pathol., 43, 1852-1865.
34. Padmanabhan,V. et al. (2004) DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J. Clin. Pathol., 57, 1057-1062.
35. Chen,C.L. et al. (2006) Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J. Pharmacol. Exp. Ther., 319, 533-542.
36. Duenas-Gonzalez,A. et al. (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat. Rev., 34, 206-222.
37. Fotiou,K. et al. (2007) Serum ceruloplasmin as a marker in prostate cancer. Minerva Urol. Nefrol., 59, 407-411.
38. Mermelshtein,A. et al. (2005) Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br. J. Cancer, 93, 338-345.
39. Takano,Y. et al. (1999) Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J. Pathol., 189, 194-200.
40. Evron,E. et al. (2001) Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res., 61, 2782-2787.
41. Virmani,A. et al. (2003) Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int. J. Cancer, 107, 341-345.
42. Fischer,H. et al. (2002) Cyclin D2 expression in familial and sporadic breast cancer. Oncol. Rep., 9, 1157-1161.
43. Matsubayashi,H. et al. (2003) Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin. Cancer Res., 9, 1446-1452.
44. Yu,J. et al. (2003) Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br. J. Cancer, 88, 1560-1565.
45. Stettner,M. et al. (2012) Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur. J. Cancer Prev., 21, 55-64.
46. Meyyappan,M. et al. (1998) Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells. Mol. Cell. Biol., 18, 3163-3172.
47. Swift-Scanlan,T. et al. (2011) Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol. Ther., 11, 853-865.